☆ 4.6 Article

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

NPJ VACCINES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Virology

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice

Juan Garcia-Arriaza et al.

Summary: Two COVID-19 vaccines based on MVA vectors induced robust and polyfunctional T-cell responses and neutralizing antibody titers in mice, providing protection against SARS-CoV-2. The results demonstrate the full efficacy of MVA-based COVID-19 vaccines in animal models and support their translation to clinical use.

JOURNAL OF VIROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Lorena Sanchez-Felipe et al.

Summary: The candidate vaccine YF-S0, utilizing the YF17D vaccine as a vector to express noncleavable prefusion form of the SARS-CoV-2 spike antigen, showed excellent safety, immunogenicity, and efficacy in animal models. It induced high levels of neutralizing antibodies, provided protective immunity against SARS-CoV-2, and prevented infection in hamsters and macaques. A single dose was able to confer protection from lung disease in most vaccinated hamsters within 10 days, highlighting the potential of YF-S0 as a potent SARS-CoV-2 vaccine candidate.

NATURE (2021)

添加到收藏夹

Article Immunology

Establishment of an African green monkey model for COVID-19 and protection against re-infection

Courtney Woolsey et al.

Summary: African green monkeys infected with SARS-CoV-2 exhibit symptoms closely resembling those in humans, making them a valuable model for studying COVID-19 pathogenesis and testing medical interventions.

NATURE IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

添加到收藏夹

Article Immunology

A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs

Nanda Kishore Routhu et al.

Summary: The study demonstrates that MVA/S vaccination induces strong neutralizing antibody and T cell responses, providing protection against SARS-CoV-2 in mice and macaques. Single-cell RNA sequencing analysis of lung cells reveals that the vaccination also protects macaques from infection-induced inflammation and B cell abnormalities.

IMMUNITY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

John P. Moore et al.

Summary: This article reviews the circulating SARS-CoV-2 genetic variants and the mechanisms of immunity by which they may escape vaccine-induced protection, proposing 6 measures to address these issues, including enhanced variant isolation and testing procedures, and continued adherence to mask-wearing and other established public health measures.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel et al.

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection

Ruikang Liu et al.

Summary: Research on modified vaccinia virus Ankara (MVA) expressing the S protein of SARS-CoV-2 showed promising results in inducing antibodies and CD8+ T cells, protecting transgenic mice from lethal infection, preventing nasal infection, reducing cytokine expression, and effectively terminating virus replication in vaccinated animals.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Correction Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity (vol 184, pg 2372, 2021)

Wilfredo F. Garcia-Beltran et al.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antibody evasion by the P.1 strain of SARS-CoV-2

Wanwisa Dejnirattisai et al.

Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.

CELL (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Correlates of protection from SARS-CoV-2 infection

Florian Krammer

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Nuno R. Faria et al.

Summary: A new variant of concern, P.1, with 17 mutations including three spike protein mutations associated with increased binding to human ACE2 receptors, emerged in Manaus, Brazil between November 2020 and January 2021. Molecular analysis suggests P.1 may be 1.7- to 2.4-fold more transmissible and that previous infection may provide 54 to 79% protection against P.1 infection compared to other lineages. Enhanced global genomic surveillance of such variants is crucial for pandemic response.

SCIENCE (2021)

添加到收藏夹

Article Immunology

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques

Paul E. Harris et al.

Summary: This study tested the efficacy of a peptide-based vaccine targeting MHC class I epitopes on the SARS-CoV-2 nucleocapsid protein using a macaque model. The results showed that vaccinated animals had lower viral loads and better immune responses when challenged with SARS-CoV-2 compared to controls. The study demonstrates that this peptide vaccine can provide protection against SARS-CoV-2 infection in nonhuman primates.

VACCINES (2021)

添加到收藏夹

Article Immunology

Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity

William E. Matchett et al.

Summary: Vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity and reduce weight loss and viral load in vaccinated Syrian hamsters and K18hACE2 mice. Vaccinated mice showed rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the idea of including additional viral antigens in SARS-CoV-2 vaccines to broaden epitope coverage and immune effector mechanisms.

JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Alina Tscherne et al.

Summary: The SARS-CoV-2 virus has caused the COVID-19 pandemic, and a recombinant MVA expressing the SARS-CoV-2 spike protein shows promise as a candidate for developing a COVID-19 vaccine.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice

Adrian Rice et al.

Summary: The study developed a dual-antigen COVID-19 vaccine that can elicit effective humoral and T-cell responses when administered subcutaneously or intranasally, with subcutaneous prime followed by intranasal or subcutaneous boost inducing greater T cell responses.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Cell Biology

Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2

Tanushree Dangi et al.

Summary: Incorporating nucleocapsid as an antigen in SARS-CoV-2 vaccines can improve acute protection in both the lungs and brain, suggesting the inclusion of nucleocapsid in next-generation COVID-19 vaccines is warranted. This finding provides important insights for the development of future vaccines against COVID-19.

CELL REPORTS (2021)

添加到收藏夹

Article Immunology

SARS-CoV-2 variants of concern partially escape humoral but not T- cell responses in COVID-19 convalescent donors and vaccinees

Daryl Geers et al.

Summary: This study suggests that some variants might partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but the S-specific CD4(+) T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

SCIENCE IMMUNOLOGY (2021)

添加到收藏夹

Article Microbiology

SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes

Raj Kalkeri et al.

Summary: SARS-CoV-2 genetic variants may reduce the neutralization efficiency of convalescent and post-vaccination sera, raising concerns about increased disease transmissibility and severity. Neutralizing antibody levels are a reliable indicator of vaccine protection, but current detection methods are time-consuming. The development of a BSL-2 pseudovirus-based neutralization assay offers a more convenient and cost-effective alternative.

MICROORGANISMS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates

So-Hee Hong et al.

Summary: A novel subunit vaccine was developed and shown to be effective in rodents and nonhuman primates. The addition of SARS-CoV-2 nucleocapsid protein enhanced the immune response of the vaccine, supporting the further development of RBD-P2 as a candidate vaccine against SARS-CoV-2.

SCIENCE ADVANCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients A Phase 2, Randomized Clinical Trial

Ibrahim Aldoss et al.

ANNALS OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

添加到收藏夹

Article Immunology

Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19)

Jasper Fuk-Woo Chan et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Immunology

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ling Ni et al.

IMMUNITY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Abishek Chandrashekar et al.

SCIENCE (2020)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Rapid COVID-19 vaccine development

Barney S. Graham

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Jingyou Yu et al.

SCIENCE (2020)

添加到收藏夹

Article Virology

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Katharine H. D. Crawford et al.

VIRUSES-BASEL (2020)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open -label, phase 1 trial

Till Koch et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sin Fun Sia et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

Vincent J. Munster et al.

NATURE (2020)

添加到收藏夹

Article Immunology

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Lakshmanane Premkumar et al.

SCIENCE IMMUNOLOGY (2020)

添加到收藏夹

Letter Virology

The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development

Noton K. Dutta et al.

JOURNAL OF VIROLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Neeltje van Doremalen et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Masaki Imai et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Review Multidisciplinary Sciences

SARS-CoV-2 vaccines in development

Florian Krammer

NATURE (2020)

添加到收藏夹

Article Immunology

Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Yanchun Peng et al.

NATURE IMMUNOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Lisa H. Tostanoski et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Virology

Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase

Robert W. Cross et al.

VIROLOGY JOURNAL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

Flavia Chiuppesi et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox

Phillip R. Pittman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Virology

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

Flavia Chiuppesi et al.

JOURNAL OF VIROLOGY (2018)

添加到收藏夹

Article Hematology

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults

Corinna La Rosa et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

Yuan Yuan et al.

ONCOIMMUNOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

Bart L. Haagmans et al.

SCIENCE (2016)

添加到收藏夹

Article Microbiology

Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex

Felix Wussow et al.

PLOS PATHOGENS (2014)

添加到收藏夹

Article Virology

A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques

Felix Wussow et al.

JOURNAL OF VIROLOGY (2013)

添加到收藏夹

Article Immunology

Clinical development of Modified Vaccinia virus Ankara vaccines

Sarah C. Gilbert

VACCINE (2013)

添加到收藏夹

Article Immunology

Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells

Stephan Halle et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

添加到收藏夹

Article Virology

Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys

J McAuliffe et al.

VIROLOGY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.